PT Tempo Scan Pacific Tbk (TSPC) Fair Value & Analysis
Industrials · ID · Market cap 11.4T IDR
Fair value as of: Jul 12, 2026
From 13 valuation models · updated 28 days ago
Fair value updated Jul 12, 2026, revised from 4,960 IDR to 5,040 IDR (+1.6%) since Jun 26, 2026. Share price +15.4% over the past month.
A solid business, screening 77% undervalued on our models.
What matters now
- The price is below even our cautious bear case (3,780 IDR). The market is more pessimistic than our downside scenario.
- Solid quality (64/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range 1,029 IDR – 2,970 IDR · fair‑value band 3,780 IDR – 6,300 IDR · the 2,850 IDR price screens below the 5,040 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 12, 2026.
Analysis
PT Tempo Scan Pacific Tbk (TSPC) currently trades at 2,850 IDR, while our model-based Fair Value estimate is 5,040 IDR, implying the stock looks roughly 76.8% undervalued today. The Quality Score stands at 64/100 (solid quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, PT Tempo Scan Pacific Tbk generated revenue of 14.1T IDR at a net margin of 9.5%. Revenue grew 4.2% year over year. It earns a return on equity of 14.2%. The balance sheet holds a net cash position of 3.6T IDR. Fundamentals as of Jul 12, 2026
Our scenario range runs from 3,780 IDR (bear case) to 6,300 IDR (bull case); at 2,850 IDR, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 11% below its 52-week high and 39% above its 52-week low, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at -14% fair-value upside, at 77%, TSPC screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 13 models by family
Widest divergence: DCF Models (6,779 IDR) versus Asset-Based (1,366 IDR). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 65 · Market factors (momentum, volatility) 73
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Tempo Scan Pacific Tbk engages in the pharmaceuticals, personal care and cosmetics, and distribution services businesses in Indonesia and internationally. The company operates through Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services segments.
Full company description
PT Tempo Scan Pacific Tbk engages in the pharmaceuticals, personal care and cosmetics, and distribution services businesses in Indonesia and internationally. The company operates through Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services segments. It is involved in the pharmaceutical and medical devices trading; manufacture of soaps, herbal products, powder milk, food and beverages, and plastic packaging; and manufacturing and trading of consumer products, cosmetics, and household products. The company sells its products under the Bodrex, Oskadon, Neo rheumacyl, Bodrexin, Contrexyn, Contrex, Oskadryl, Vidoran, Neodulax, Vidoran, Hemaviton, Neo Hormoviton, Polaris, Vitonal, Vitamin IPI, Neo rheumacyl Herbal, Wybert Herbal, Bodrexin Herbal, Herbalax, Marina, Natural Honey, Claudia, Total Care, and ULTIMA II brands. It also engages in the construction and rental of buildings; Trading, fresh milk processing, livestock, and agriculture; cosmetics retailer and e-commerce; advertising and promotion, research and development, and information technology and communication network systems services; and procurement, distribution, and marketing activities. The company was formerly known as PT Scanchemie. PT Tempo Scan Pacific Tbk was founded in 1970 and is based in Jakarta, Indonesia. The company operates as a subsidiary of PT Bogamulia Nagadi.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Tempo Scan Pacific Tbk reported revenue of 14.0T IDR in FY2025 versus 11.2T IDR in FY2021, a compound +5.7%/yr. Reported net income was 1.4T IDR in FY2025, compounding +14.3%/yr from FY2021.
Watch TSPC: get an alert when its fair value changes →
Peer Group
Conglomerates · 370 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Conglomerates median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Conglomerates stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| CITIC Limited 0267 | HK$11.28 | HK$22.56 | +100% |
| Swire Pacific Limited 0019 | HK$99.50 | HK$16.77 | -83% |
| SK Inc 034730 | 580,000 KRW | 497,919 KRW | -14% |
| PT Astra International Tbk, ASII | 4,810 IDR | 9,620 IDR | +100% |
| Grupo Carso, S.A. GCARSOA1 | 127.02 MXN | 66.21 MXN | -48% |
| The Siam Cement Public Company SCC | 254.00 THB | 199.40 THB | -21% |
| SRF Limited SRF | ₹2,875 | ₹1,053 | -63% |
| Empresas Copec S.A COPEC | 6,330 CLP | 10,879 CLP | +72% |
| Posco International Corporation 047050 | 50,900 KRW | 61,248 KRW | +20% |
| Tube Investments of India Limited TIINDIA | ₹2,940 | ₹559.30 | -81% |
Compare PT Tempo Scan Pacific Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is PT Tempo Scan Pacific Tbk (TSPC) overvalued or undervalued?
What is the fair value of TSPC?
What is the quality score of TSPC?
What is the revenue of PT Tempo Scan Pacific Tbk (TSPC)?
What is the net profit margin of TSPC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Tempo Scan Pacific Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.